期刊名称:The Open Pharmacoeconomics & Health Economics Journal
电子版ISSN:1876-8245
出版年度:2013
卷号:5
期号:1
页码:11-14
DOI:10.2174/1876824501305010011
出版社:Bentham open
摘要: Objectives: To estimate the annual cost of productivity losses per person with RA by 0.5 increment in HAQscore,
and the annual cost of productivity losses for Alberta province.
Methods: Using data from the Alberta Biologics Registry - a prospective observational cohort of consecutive patients
receiving DMARD or anti-TNF therapies created in 2004, we compared the mean and median costs of productivity losses
per patient per year between HAQ-score categories using multiple linear and quantile regressions, respectively. We used a
prevalence-based approach to estimate the cost (in 2010 CA$) of productivity losses of RA for Alberta.
Results: In total there were 1222 patients with RA interviewed at the baseline. Of this, 358 were the "current employees"
and 204 were the "previous employees" totalling 563 patients for analyses. For all HAQ-score categories, the mean
(median) of the cost per patient per year was estimated at $18,242 ($3,840). The cost was increasing along with the HAQscore
increase. The lowest cost ($6,295) was found in category HAQ2.0. The significant differences were found between the worse categories (HAQ>1.5) and the better categories
(HAQ
Conclusion: The results suggest that an improvement in the controlling of RA could have a significant economic impact in
Alberta and that preventing HAQ-score from the worse categories may be associated with substantial savings in terms of
productivity losses.